학술논문
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Document Type
Article
Author
Fukushima, Y; Hamamoto, Y; Hisatomi, A; Ide, Y; Inoue, S; Kawada, T; Kim, H; Kiyosue, A; Matoba, K; Matsuoka, O; Nishimura, H; Noguchi, M; Osonoi, T; Sawada, S; Shibasaki, Y; Shin, K; Yamada, Y; Yamada, Yuichiro ; Katagiri, Hideki; Hamamoto, Yoshiyuki; Deenadayalan, Srikanth; Navarria, Andrea; Nishijima, Keiji; Seino, Yutaka
Source
In The Lancet Diabetes & Endocrinology May 2020 8(5):377-391
Subject
Language
ISSN
2213-8587